Nephrocare Health Services Q4 FY26 Results: PAT Rs 30 Cr

Nephrocare Health Services Q4 FY26 results were declared on May 19, 2026. Nephrocare Health Services reported PAT of Rs 30 crore up 20.0% YoY from Rs 25 crore in Q4 FY25, on revenue of Rs 266 crore for the quarter ended March 31, 2026. Nephrocare Health Services is a Dialysis Healthcare company listed on Indian stock exchanges. This article covers the complete Nephrocare Health Services Q4 FY26 financial highlights, key performance factors, and FY27 outlook for investors tracking Nephrocare Health Services.

Click Here – Get Free Investment Predictions

Nephrocare Health Services Q4 FY26 Financial Highlights

Metric	Q4 FY26	Notes
PAT	Rs 30 crore	up 20.0% YoY from Rs 25 crore in Q4 FY25
Revenue	Rs 266 crore	for the quarter ended March 31, 2026

Note: Q4 FY26 PAT Rs 30 crore (+20% YoY) on revenue Rs 266 crore. Dialysis centre chain. Strong patient volume growth.

Nephrocare Health Services Q4 FY26 Performance Analysis

The Nephrocare Health Services Q4 FY26 results reflect Nephrocare Health Services’s operational performance during the January to March 2026 quarter. The company operates in the Dialysis Healthcare space, a sector supported by India’s strong GDP growth and domestic demand. The Q4 FY26 results demonstrate continued business execution and operational resilience.

Screen the best stocks on the Univest Screener.

Investors tracking Nephrocare Health Services Q4 FY26 will focus on FY27 revenue guidance, margin trajectory, and management’s capital allocation commentary. Track Nephrocare Health Services on the Univest Screener for live fundamentals and real-time updates.

Key Business Factors for Nephrocare Health Services Q4 FY26

Revenue and Operational Performance

Nephrocare Health Services Q4 FY26 performance reflects the January to March 2026 quarter, historically the year-end quarter with strong order execution and seasonality effects. India’s macroeconomic environment with GDP growth above 6.5% provided a constructive backdrop for the Dialysis Healthcare sector during this period.

Profitability and Margin Trends

the company PAT of Rs 30 crore up 20.0% YoY from Rs 25 crore in Q4 FY25. Sustaining profitability and improving operating margins will be key watchpoints for FY27 performance.

India Economic Context for Nephrocare Health Services

The January to March 2026 quarter saw strong domestic consumption, fiscal year-end capital expenditure cycles, and government infrastructure spending. The Reserve Bank of India’s supportive monetary stance and India’s resilient growth trajectory provided a stable environment for listed companies across sectors. For Nephrocare Health Services, operating in the Dialysis Healthcare space, this macro backdrop supported demand conditions during the quarter.

FY27 Outlook and Growth Drivers

Following the listed company results, management commentary on FY27 revenue guidance, capex plans, and order pipeline will be the primary catalysts for investor sentiment. The Dialysis Healthcare sector continues to benefit from India’s structural growth, rising domestic consumption, and government policy support.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the group

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.